Media

Amber

Amber International Holding Reports 69.8% Increase in Client Assets and Announces Share Repurchase Program

Amber released FY2024 9 Months earnings on November 26 (EST), actual revenue USD 2.679 M, actual EPS USD -0.1887

Amber released FY2024 Q3 earnings on November 26 (EST), actual revenue USD 801 K, actual EPS USD -0.0134

Amber released FY2025 9 Months earnings on November 26 Pre-Market (EST), actual revenue USD 52.2M, actual EPS USD 0.0379

Amber released FY2025 Q3 earnings on November 26 Pre-Market EST with actual revenue of USD 16.3 M and EPS of USD 0.0161

Amber and Trade Desk See Gains in After-Hours Trading, Comcast Shares Fluctuate Due to Data Breach

Amber to Release FY2025 Q3 Earnings Report on November 26, Pre-Market EST

Amber International Holding Limited Announces Progress in Crypto Financial Services

Amber International Launches Full-Stack Real World Assets Solution

Amber to Release FY2025 Q2 Earnings Report on September 10, Pre-Market EST

Amber International becomes the first listed crypto company in Asia

Amber International Holding Submits $500 Million Shelf Offering Application

Amber International Completes $25.5 Million Private Placement

Amber International Holding Limited Successfully Completes $25.5 Million Private Placement

Amber released FY2024 Semi-Annual earnings on June 12, 2025 (EST), with actual revenue of USD 1.878 M and EPS of USD -0.1668

Amber released FY2024 Q2 earnings on June 12 (EST), actual revenue USD 867 K, actual EPS USD 0.0247

Amber released FY2025 Semi-Annual Earnings on June 12 Pre-Market (EST), actual revenue USD 35.9 M, actual EPS USD 0.021

Amber released FY2025 Q2 earnings on June 12 Pre-Market (EST), actual revenue USD 20.96 M, actual EPS USD 0.0081

Amber International and DeFi Development Sign Memorandum of Understanding for Enhanced Solana Market Access

Amber released FY2024 Q1 earnings on May 28 (EST), actual revenue USD 1.011 M, actual EPS USD -0.2

Cemtrex

Top Wealth

Wave Life Sciences

Structure Therapeutics

Fulcrum Therapeutics

iBio

Kymera Therapeutics

Paranovus ENT Tech

Webuy Global

GCI LIBERTY INC COM USD0.01 SER C SUBS RTS 17/12/2025

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap